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Abstract
Surgical site infection (SSI) is a common type of health-care–associated infection (HAI) and adds considerably
to the individual, social, and economic costs of surgical treatment. This document serves to introduce the
updated Guideline for the Prevention of SSI from the Centers for Disease Control and Prevention (CDC) and
the Healthcare Infection Control Practices Advisory Committee (HICPAC). The Core section of the guideline
addresses issues relevant to multiple surgical specialties and procedures. The second procedure-specific section
focuses on a high-volume, high-burden procedure: Prosthetic joint arthroplasty. While many elements of the
1999 guideline remain current, others warrant updating to incorporate new knowledge and changes in the
patient population, operative techniques, emerging pathogens, and guideline development methodology.
Keywords: infection; prevention; surgical site infection
Surgical site infections (SSIs), defined as infectionsanatomically associated with a surgical procedure per-
formed in an operating room and not present before opera-
tion, remain an important problem for both patients and the
healthcare system. Among an estimated 27 million surgical
procedures performed each year in the United States, SSIs
occur at a rate of 2 per 100 procedures, or approximately
500,000 per year [1,2]. These infections lead to increased
duration of hospitalization, costs, morbidity, and risk of
death. The average SSI, whether detected during the ini-
tial hospitalization or post-discharge and resulting in re-
admission, is associated with approximately one additional
week of hospitalization and increases risk of death two to
11-fold compared with uninfected surgical patients [3,4].
SSIs caused by resistant organisms such as methicillin-
resistant Staphylococcus aureus (MRSA) lead to even worse
outcomes [5]. Each SSI costs approximately $12,000–$35,000
(2007 US dollars) to manage, with an annual total cost to the
US healthcare system of approximately $10 billion [6]. As part
of ongoing efforts to reduce the incidence and burden of SSIs,
the Centers for Disease Control and Prevention (CDC) and the
Healthcare Infection Control Practices Advisory Committee
(HICPAC) have updated recommendations for the prevention
of these infections [6–9].
Historical perspective: Is there a need
for a new guideline?
Infection control activities became commonplace in the
1960s, with hospitals constructing individualized programs
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in the absence of standardized definitions of events such as
SSIs [10]. In 1964, the National Research Council (NRC)
sponsored a study evaluating the efficacy of ultraviolet irra-
diation that provided data validating a wound classification
scheme that described the risk of SSI in relation to the extent
of wound contamination. [11]. A clear connection between
the contaminating flora at various surgical sites and subse-
quent infecting pathogens was established. That landmark
document’s classification scheme remains in use today.
In 1983, CDC published the Guideline for Prevention of
Surgical Wound Infections [8,9]. This guideline addressed
only incisional wound infections; recommendations were
based primarily on expert opinion. The 1985 revision clarified
ambiguities in the previous guideline and provided new in-
formation on pre-operative hair removal and operating room
ventilation [12]. The 1999 guideline adopted the term ‘‘sur-
gical site infection’’ [6,7]. This guideline, cited by more than
2,500 publications, has served as the foundation for individual
professional society guidelines, hospital infection control
teams, and for the generation of national quality metrics by
key organizations such as the Institute for Healthcare Im-
provement (IHI) and the National Quality Forum.
While many elements of the 1999 guideline remain current,
others warrant updating to incorporate new knowledge as well
as changes in patient populations, operative techniques,
emerging pathogens, and guideline development methodol-
ogy. The background health of the US population clearly has
changed, with increasing incidences of obesity, diabetes mel-
litus, and other metabolic diseases [13–18]. The dramatic in-
crease in the use of minimally invasive surgical techniques and
implants may require a different approach to SSI prevention
for those procedures [19–23]. The emergence of MRSA and
other antimicrobial resistant pathogens may impact the rate
and severity of SSI as well as potential prevention strategies
[24]. Finally, more rigorous methodologic approaches to
guideline development have been established, calling for sig-
nificant input from stakeholders in addition to experts in the
field. These approaches are important in securing the confi-
dence of professional organizations and providers, especially
because evidence-based practice guidelines are increasingly
applied to monitor the quality of healthcare delivery.
A national action plan to prevent health-care–associated
infections (HAIs) has been developed [25]. The updated SSI
guideline addresses concerns raised in the Health and Human
Services plan. Beginning in 2012, hospitals participating in
the Centers for Medicare & Medicaid Services (CMS) In-
patient Prospective Payment System were required to report
SSI data related to two procedures—total abdominal hys-
terectomy and colon operations—through CDC’s National
Healthcare Safety Network (NHSN) surveillance system.
These data are included in the Inpatient Quality Reporting
data publicly reported by CMS through the Hospital Compare
Web site [26].
Care bundles
Care bundles are a collection of standardized clinical
practices that individually have been shown to improve pa-
tient outcome. When implemented together, they are be-
lieved to result in a superior outcome compared with
implementation of individual measures. The concept of care
bundles was developed by the IHI to improve the reliability
of delivery of essential healthcare processes [27,28]. Based
on the IHI definition, a bundle is composed of three to five
level 1 evidence elements. The expressed purpose of care
bundles was to reduce practice variation and simultaneously
improve overall quality of care and outcomes [29].
Currently, certain initiatives make implementation of
specific care bundles mandatory or nearly so. Payers, such
as CMS, increasingly are monitoring compliance with care
bundles, such as process measures from the Surgical Care
Improvement Project, both as a publicly reportable quality
measure and as a tool to determine remuneration for certain
medical services [26,30].
New approach to the guideline
In addition to the Core section addressing topics and rec-
ommendations applicable across surgical procedures, the
guideline includes a new, procedure-specific section, focused
on a single high-volume, high-burden procedure. The new
structure is meant to serve as a targeted and effective way to
provide timely guideline development, updates, and re-
sponses to emerging needs in addressing key clinical ques-
tions without requiring an update of the full guideline [31].
The procedure-specific section focuses on prosthetic joint
arthroplasties. Approximately 1.2 million arthroplasties are
performed in the United States annually [32]. In upcoming
years, it is projected that there will be significant increases in
the number of prosthetic joint arthroplasties performed, as
well as their related SSIs and cost of treatment [32–36].
Methodology
Since 2009, CDC and HICPAC have utilized a new,
evidence-based guideline development methodology [31].
The methodology includes generating key questions based on
external expert opinion, performing targeted systematic re-
views of the best available evidence, and providing an explicit
link between the evidence and the resultant recommendations
using a modified Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) method [37]. The
GRADE system determines the strength of a recommendation
based on the rigor of the individual studies. The largest weight
is provided to high-quality, randomized studies but can in-
clude observational studies. In the case of meta-analyses, the
component studies are analyzed to assure proper inclusion and
analysis methodology.
There are several benefits to applying the level of rigor
characteristic of the GRADE methodology to the develop-
ment of recommendations. Most important, it is a transparent,
systematic process that provides confidence for making clear
policy statements regarding high-level recommendations. In
addition, the GRADE system identifies specific recommen-
dations in which there is a possibility of future change based
on further data, and allows for the easy identification of ev-
idence gaps and elaboration of future research priorities.
Potential shortcomings of the GRADE system relate to
whether the bar for high-level evidence is set realistically to
infection control strategies that may be difficult to study and
are therefore rarely subjected to rigorous randomized con-
trolled trials. Some core practices of infection prevention—
for example, practices that confer greater likelihood of
asepsis—may be unethical to study via randomized con-
trolled trials; recommendations in support of these practices















































must be made on a different basis than other recommenda-
tions, thereby giving the appearance of a less objective,
systematic approach of applying GRADE criteria in fields of
infection prevention and public health.
Participants
In addition to CDC, HICPAC, its non-voting liaisons, and
ex-officio members from professional organizations and
other federal agencies, a multi-disciplinary team of 35 SSI
prevention experts have contributed to the process. There is
official representation by the American College of Surgeons,
the American Academy of Orthopaedic Surgeons, the Sur-
gical Infection Society–North America, the Musculoskeletal
Infection Society, and the Association of periOperative Re-
gistered Nurses. Additional national and international experts
provided expertise in general and orthopedic surgery, S. au-
reus colonization, biofilm, and environmental sciences. The
University of Pennsylvania Health System’s Center for
Evidence-based Practices provided expertise in evidence-
based methodology and together with CDC and HICPAC
leads, comprised the core writing group.
Dissemination
Previous CDC and HICPAC SSI guidelines were published
in infection control journals [7,12,38] followed by summary
statements in the surgical literature [8,39]. In 1983, Simmons
stated: ‘‘.to prevent surgical wound infections, personnel who
perform the operation must take the lead in instituting pre-
vention measures’’ [9]. To engage further the surgical com-
munity and capitalize on the multi-disciplinary collaboration
already established in the guideline development process,
publishing in the general and orthopedic surgery literature will
be important. In addition, the full guideline with recommen-
dations, evidence, and GRADE tables will be available for free
download on the CDC website.
This is one of two additional articles being published with
the guideline, authored by leaders in SSI prevention who
served as content experts on the guideline. These documents
complement the updated guideline structure, now focused on
the evidence-based recommendations and GRADE tables.
This introductory article describes relevant changes in no-
menclature, epidemiology, risk factors, pathogenesis, and the
rationale for use of the GRADE system to generate recom-
mendations. The ‘‘Priority Surgical Site Infection Prevention
Research Opportunities’’ article compiles potential research
questions based on evidence gaps identified. These articles
reinforce the collaboration between clinical and public health
in the guideline development process and additional ques-




The first formal definition of a wound infection was
‘‘pus in the wound’’ [11]. In 1992, the CDC definition of
infection at the surgical site expanded from ‘‘wound in-
fection’’ to ‘‘surgical site infection’’ [40]. The change in
nomenclature was introduced to provide a single term to
include both incisional (superficial or deep) and organ/
space infections. These SSI definitions were originally
developed for use by hospitals reporting data to CDC’s
National Nosocomial Infection Surveillance system, a
precursor to the NHSN Patient Safety Component [40].
NHSN launched in 2005.
The impact of an SSI on both the patient and healthcare
system varies by infection type. Several studies have shown
that the number of infections detected increases the longer
that surveillance is continued after discharge [41]. Superficial
incisional SSIs often do not require hospitalization and are
inconsistently diagnosed by post-discharge surveillance
[42,43]. Collectively, deep incisional and organ space in-
fections are considered ‘‘complex’’ SSIs. In most series,
complex SSIs represent about one-third to one-half of SSIs,
although this varies according to procedure (Table 1).
Complex SSIs typically require re-hospitalization, drainage
or debridement, and systemic antimicrobial therapy. These
infections generate considerable morbidity, cost, and even
death. Unfortunately, many surveys examining incidence,
cost, morbidity, or death do not make a distinction between
complex and superficial SSIs.
Incidence
Systematic study of the incidence of SSIs dates to the
1950s [44,45]. Much of this work focused on S. aureus, in-
cluding investigations into the role of nasal colonization as a
risk factor for infection [46]. Cruse and Foord [47,48] per-
formed a 10-year, prospective study of wound infections after
operation across multiple surgical services at a large teaching
hospital. Using the NRC wound classification schemes, they
noted that infection rates were <2% for ‘‘clean wounds,’’
6%–9% for ‘‘clean-contaminated wounds,’’ 13%–20% for
‘‘contaminated wounds,’’ and approximately 40% for ‘‘dirty
wounds.’’ Their work also supported the notion that reporting
surgeon-specific SSI rates was associated with reduced in-
fection rates [48–51]. Other single institution studies con-
firmed these findings [51–53].
Surveillance is a tool to ensure that hospital systems are
working properly and that interventions taken to reduce the
risk of HAIs are working [54]. National public reporting
through NHSN focuses on procedure risk adjusted, category-
specific, and combined deep incisional and organ/space SSIs
(Table 1). The NRC ‘‘clean, clean-contaminated, contami-
nated, dirty’’ classification scheme is not used in public re-
porting.
Risk factors
Although debate remains over best methods, it is a well
accepted that risk adjustment should be based on patient-
specific factors and be consistently applied [55]. Risk factors
for the development of SSI are typically divided into patient-
related (pre-operative), procedure-related (peri-operative), and
post-operative categories (Table 2). In general, patient-related
risk factors for SSI can be categorized as either modifiable
(e.g., poorly controlled diabetes mellitus, obesity, tobacco use,
length of pre-operative hospitalization, and colonization) or
non-modifiable (e.g., age). Procedure-related risk factors in-
clude, but are not limited to: wound class, organ site, and
length of operation. Post-operative risk factors can include
wound care, post-operative blood transfusions, and hypergly-
cemia in both diabetic and non-diabetic patients. Efforts to
improve risk modeling are ongoing [2,56,57].
















































Understanding of the pathogenesis of SSI has changed
substantially since the 1999 guideline. The concept of a
‘‘microbiome,’’ the hypothesis that we live within and interact
with cohorts of micro-organisms in a commensal relationship,
has been well established [57]. Several different bacterial and
fungal commensals can become pathogenic when they create
biofilms, structured communities within three-dimensional
matrices of extracellular polymeric substances [58]. Biofilms
have significantly increased resistance to key mechanisms of
innate host defense and antimicrobial agents [59]. Biofilm
formation, for which there is currently no preventive strategy,
is a key variable in infections with implanted devices and may
remain under-recognized as a factor in all infections.
Recent efforts have been undertaken to understand the
molecular basis of biofilm formation in staphylococci, which
cause frequent biofilm-associated infections [60]. The de-
velopment of a bacterial biofilm involves an initial micro-
bial attachment and a subsequent maturation phase. A final
detachment phase, which involves the separation of single
Table 1. Surgical Site Infection Rates for Select Procedures, Deep Incision and Organ/Space Infections,
Detected on Admission or Re-Admission, National Healthcare Safety Network, 2014*
Infections
Procedure Procedures, n n Rate (%)
Abdominal
Bile duct, liver, or pancreatic operation 10,228 328 3.2
Colon operation 300,526 8,952 3.0
Small bowel operation 22,058 453 2.1
Rectal operation 6,561 112 1.7
Herniorrhaphy 16,134 140 0.87
Gastric operation 31,494 228 0.72
Cholecystectomy 65,079 272 0.41
Neurologic
Ventricular shunt 7,399 143 1.9
Vascular
Peripheral vascular bypass surgery 8,755 198 2.2
Spine
Refusion of spine 5,740 85 1.4
Spinal fusion 110,975 793 0.71
Laminectomy 100,750 361 0.35
Cardiac
Coronary artery bypass grafta 117,972 796 0.67
Breast
Breast operation 13,801 148 1.1
Arthroplasty procedures
Hip prosthesis 291,628 2,006 0.69
Knee prosthesis 417,937 1,547 0.38
Obstetric and gynecologic
Abdominal hysterectomy 307,648 2,020 0.66
Cesarean section 211,468 329 0.16
Ovarian operation 32,082 26 0.08
*Surgical site infections included are those classified as deep incisional or organ/space infections after inpatient procedures that occurred
in 2014 with a primary skin closure technique, detected during the same admission as the surgical procedure or on re-admission to the same
facility. Preliminary analysis based on data available at 9/2015. Data from Centers for Disease Control and Prevention health-care–
associated infections (CDC HAI) Progress Report www.cdc.gov/hai/surveillance/progress-report/index.html (last accessed March 20,
2017); and CDC HAI Progress Report data tables, ‘‘Table 2b SSIs from all NHSN procedure categories from Acute Care Hospitals,’’ www
.cdc.gov/hai/excel/hai-progress-report/hai-progress-tables.xlsx (last accessed March 20, 2017).
aCoronary artery bypass graft includes procedures with either SSI of chest only or chest and donor site incisions.
Table 2. Established Risk Factors
for Surgical Site Infections
Patient-related factors
Age [79–80]
Obesity or malnutrition [55,80,81]




Pre-operative hospital stay [89]
Procedure-related factors
Instrument cleaning, decontamination, and sterilization
Operating room ventilation [90]
Pre-operative shaving [91]






















































cells or cell clusters by various mechanisms, is considered to
be crucial for the dissemination of bacteria to secondary sites
of infections. Detached biofilm bacteria may establish sec-
ondary biofilm infections elsewhere, which can possibly be
of greater severity.
S. aureus: High-risk pathogen
The micro-organisms causing SSIs are well known [61].
Staphylococcal species are the predominant pathogens in all
but gastrointestinal procedures (Table 3). In those procedures,
particularly those involving the small and large intestines,
Escherichia coli, Pseudomonas aeruginosa, Klebsiella spp.,
and other facultative aerobes predominate.
Staphylococcus aureus is an extraordinarily versatile path-
ogen that can survive in hostile environmental conditions,
colonize mucous membranes and skin, and cause severe, non-
purulent, toxin-mediated disease or invasive pyogenic infec-
tion. There has been rapid appearance and spread of a particular
genotype of S. aureus, which in the United States is predomi-
nately the USA300 strain [62]. A variety of surface protein
adhesins, excreted toxins, and complex translational and tran-
scriptional regulatory systems allow this strain to be a highly
virulent and common pathogen in skin and soft tissue infec-
tions, SSIs, pneumonia, bacteremia, and osteomyelitis [63–65].
The incidence of soft tissue and pulmonary infections from
community-associated MRSA has increased dramatically,
particularly in children and young, immunocompetent adults
[66]. Although initially described as community-associated or
community-onset MRSA, this strain is now quite common in
healthcare settings and is replacing other strains of MRSA as a
cause of HAIs [63–65]. The USA300 strain also has become a
common pathogen for SSIs; it is the most common form of S.
aureus found in SSIs in hospitalized patients [67,68]. Methods
to reduce the risk of infection because of this organism are an
important focus for clinical research.
Hyperglycemia as a key risk factor for SSIs
The increase in obesity and decrease in physical activity
underlies the alarming rise in the incidence of diabetes mel-
litus [69]. The increasing incidence of this disease, and its
hallmark, hyperglycemia, is associated with increased in-
fection rates [70,71].
The mechanisms by which hyperglycemia produces end-
organ damage are now well understood [72]. Hyperglycemia
has been known since the early 1960s to cause oxidative
stress [73]. The term ‘‘oxidative stress’’ refers to an imbal-
ance between the production of reactive oxygen species and
their resultant damage and a biologic system’s ability to de-
toxify these reactive intermediates and correct the resulting
injury [74]. Certain cell types, such as capillary endothelial
cells in the retina, mesangial cells in the renal glomerulus,
and neurons and Schwann cells in peripheral nerves, are
particularly vulnerable to these reactive oxygen species, ex-
plaining the organ-specific damage seen in diabetes mellitus
Table 3. Percent of Surgical Site Infections with Select Pathogen, by Procedure Category,
Deep Incision and Organ Space Infections, Detected on Admission or Re-Admission,
National Healthcare Safety Network, 2011*,**
Procedure category
All Orthopedic Abdominal Cardiac Ob/gyn Neurologic
Pathogen N % N % N % N % N % N %
Staphylococcus aureus
MSSAa 1,656 14.2 1,112 24.9 131 3.1 272 20.3 35 4.1 61 19.6
MRSAa 1,199 10.3 779 17.4 141 3.3 193 14.4 34 4.0 21 6.7
Escherichia coli 1,184 10.2 203 4.5 773 18.1 55 4.1 123 14.4 8 2.6
Coagulase-negative staphylococci 1,084 9.3 601 13.5 128 3.0 194 14.5 45 5.3 78 25.0
Enterococcus faecalis 691 5.9 174 3.9 383 9.0 38 2.8 76 8.9 4 1.3
Pseudomonas aeruginosa 561 4.8 169 3.8 210 4.9 104 7.8 29 3.4 14 4.5
Klebsiella pneumoniae
(and K. oxytoca)
491 4.2 92 2.1 285 6.7 54 4.0 29 3.4 11 3.5
Enterobacter spp. 483 4.1 168 3.8 185 4.3 76 5.7 20 2.3 13 4.2
Enterococcus spp. 410 3.5 73 1.6 256 6.0 18 1.3 35 4.1 2 0.6
Enterococcus faecium 290 2.5 39 0.9 201 4.7 15 1.1 7 0.8 2 0.6
Candida albicans 218 1.9 12 0.3 157 3.7 19 1.4 14 1.6 5 1.6
Other Candida spp. or NOS 124 1.1 17 0.4 82 1.9 13 1.0 2 0.2 2 0.6
Acinetobacter baumanii 40 0.3 21 0.5 6 0.1 6 0.4 2 0.2 2 0.6
Other 3,122 26.8 941 21.1 1,320 31.0 267 19.9 397 46.6 87 27.9
TOTAL 11,650 100 4,468 100 4,264 100 1,341 100 852 100 312 100
*Preliminary analysis based on data available in 9/2012.
**The types of surgery included in each category are as follows: Orthopedic: open reduction of fracture, hip prosthesis, knee prosthesis,
limb amputation, spinal fusion, refusion of spine, and laminectomy; abdominal: appendectomy, bile duct, liver, or pancreatic operation,
gallbladder operation, colon operation, gastric operation, herniorrhaphy, small-bowel operation, spleen operation, abdominal operation, and
rectal operation; cardiac: cardiac operation, coronary artery bypass graft with chest incision with or without donor incision, pacemaker
operation, and thoracic operation; obstetric/gynecologic (Ob/gyn): cesarean section, abdominal hysterectomy, ovarian operation, and
vaginal hysterectomy; neurologic: craniotomy and ventricular shunt.
aMRSA denotes methicillin resistant S. aureus, defined as resistant to methicillin, oxacillin, or cefoxitin; MSSA denotes not resistant to
these antibiotics.















































[75]. In addition, oxidative stress leads to the production of
advanced glycation end-products, which are sensed as a
‘‘damage’’ signal by endothelial cells. These trigger an in-
flammatory reaction [76]. Sterile inflammation has a well-
recognized role as an adjuvant for the establishment of tissue
invasive infection at low organism densities, leading to an
overall increased susceptibility to infection in patients with
diabetes mellitus.
Can We Get to Zero SSI?
We are now in an era of zero tolerance for HAIs. Even
though SSI rates are unlikely to ever be zero, this is an im-
portant agreed on aspirational goal for improving patient
safety. Despite current movement by CMS to link SSI reduc-
tions to payment incentives, we are likely to face many chal-
lenges in reducing SSIs, including the increasing proportion of
infections caused by antimicrobial-resistant pathogens such as
MRSA. This may, in turn, reflect increasing numbers of se-
verely ill and immunocompromised surgical patients as well as
the impact of poor antimicrobial stewardship through unnec-
essary widespread use of broad-spectrum antimicrobial agents.
Even if it is not possible currently to conceive of a time when
there will be zero SSIs, this remains a useful goal for the future.
The goal of zero SSIs promotes not only prevention of the SSIs
currently preventable using existing strategies, but also the
research necessary to discover future strategies that can pre-
vent the remaining fraction of infections.
Summary
There have been important changes in the epidemiology of
SSI in the United States and elsewhere in the world since
publication of the previous guideline in 1999. These include
changes in risk factors for SSI, particularly the increased
resistance and virulence of infecting organisms and the in-
creasing use of surgical procedures in vulnerable patients at
risk for infection because of underlying diseases such as
obesity and diabetes mellitus. There have also been new in-
sights into microbial mechanisms of infection as well as the
mechanisms by which some disease processes lead to in-
creased rates of infection. These developments warrant re-
view, addition to, and, in some places, revision of previous
recommendations for the prevention of SSI.
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